To view a more complete list of Paul Capital Healthcare's investments, please visit the Portfolio Investments section.

	Acorda Therapeutics A revenue interest transaction finances a sales force expansion while strengthening a company's pre-IPO financial position
	AVANT Immunotherapeutics (now Celledex Therapeutics) A public company unlocks value through a royalty monetization
	Dyax Corp. Monetizing a basket of future royalties, milestone payments and license fees generated by a company’s platform technology
	Oscient Pharmaceuticals Revenue interest, debt and equity hybrid investment provides a balanced cost of capital and funds a transformational strategic product acquisition
	Plethora Solutions Holding PLC A specialty pharma company uses future product revenues to offset its near-term Phase III development costs
	Vernalis PLC Leveraging future revenues to rebuild shareholder value
	Verus Pharmaceuticals An equity and revenue interest hybrid investment funds a private company’s product acquisition while keeping its post-money valuation low
	SpePharm Aquiring the financial and commercial resources to build a leading pan-European specialty pharmaceutical company